NLS Pharmaceutics Ltd.

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.1393 ^USD	-1.55%		+0.94%	-76.39%

08/04	Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	CI
03/04	NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	CI

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors

April 09, 2024 at 01:42 am IST

On April 3, 2024, Mr. Anthony S. Walsh, Ph.D. resigned as a member of the board of directors, or the Board, of NLS Pharmaceutics Ltd., or the Registrant. The company does not intend to replace Mr. Walsh with a new member of the Board.

Latest news about NLS Pharmaceutics Ltd.

Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors	09/04	CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding	03/04	CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding	20/03	CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance	23/02	MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023	07/12	CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	02/12	MT
Sector Update: Health Care Stocks Rise in Afternoon Trading	02/12	MT
Top Midday Gainers	02/12	MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise	01/12	MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value	17/11	CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy	14/23/14	MT
Top Premarket Gainers	31/23/31	MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022	19/23/19	CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday	03/23/03	MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3	03/23/03	MT
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol	03/23/03	CI
NLS Pharmaceutics Ltd. Approves Board Appointments	01/23/01	CI
NLS Pharmaceutics Says Drug Interaction Studies of Mazindol Show 'Positive Results'	14/23/14	MT
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol	14/23/14	CI
NLS Pharmaceutics AG Announces Executive Changes	25/23/25	CI
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer	08/23/08	CI
NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer	06/23/06	CI
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2022	06/23/06	CI
NLS Pharmaceutics Receives Green Light from the U.S. Food and Drug Administration to Proceed with Phase 3 Clinical Program for Quilience(R) for the Treatment of Narcolepsy	02/23/02	CI
NLS Pharmaceutics Ltd. Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2	27/23/27	CI

Chart NLS Pharmaceutics Ltd.

Duration

Period

More charts

Company Profile

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
NLS PHARMACEUTICS LTD.	-76.39%	6.57M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research